Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Board declares interim dividend of Rs 2 per equity share
The company has reported total income of Rs.826.40 crores for FY 2020-21
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Subscribe To Our Newsletter & Stay Updated
